# A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine

> **NCT02959177** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 459 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Galcanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02959177
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-09
- **Primary completion:** 2019-01-18
- **Final completion:** 2019-01-18
- **Target enrollment:** 459 (ACTUAL)
- **Last updated:** 2021-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02959177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02959177, "A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02959177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*